Table 1 Baseline demographics, efficacy population (N = 19).

From: A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma

Age in years, median (range)

67.5 (23.3–81.8)

Gender, n (%)

 

 Male

19 (100)

 Female

0 (0)

Extrahepatic disease, n (%)

 

 No

4 (21)

 Yes

15 (79)

ECOG PS, n (%)

 

 0 

12 (63)

 1

7 (37)

Baseline serum albumin in g/dl, median (range)

4.0 (3.3–4.7)

Baseline serum bilirubin in mg/dl, median (range)

0.9 (0.3–1.9)

Baseline serum AFP in ng/ml, median (range)

394.4 (3.3–200,000.0)

  1. AFP α-fetoprotein, ECOG Eastern Cooperative Oncology Group, PS performance status.